When Is FDA Form 3486 Required? (w/Examples) + FAQs

FDA Form 3486 is required whenever a biological product deviation (BPD) occurs that may affect the safety, purity, or potency of a distributed product. The form must be submitted within 45 calendar days of discovering the deviation—this applies to licensed biological product manufacturers, blood establishments, transfusion services, and human cells, tissues, and cellular and tissue-based products (HCT/P) establishments. Missing this deadline triggers FDA enforcement actions that can escalate from warning letters to consent decrees and product seizures.

The regulatory framework governing this requirement exists under three separate but related provisions: 21 CFR 600.14 for licensed biological products other than blood, 21 CFR 606.171 for blood establishments and transfusion services, and 21 CFR 1271.350(b) for HCT/Ps regulated under section 361 of the Public Health Service Act. These regulations create mandatory reporting obligations that, if ignored, result in adulterated product classifications and potential criminal penalties.

According to FDA’s FY2024 annual summary, biological product and HCT/P deviation reports totaled 16,993 submissions—a 4.5% increase from the previous year. Blood and Source Plasma establishments alone submitted 96% of all reports, with 2,611 establishments filing at least one deviation report during the fiscal year.

In this article, you will learn:

📋 Which specific events trigger mandatory FDA Form 3486 reporting and which situations do not require a report

⏰ The exact 45-day timeline requirements and how to calculate your deadline based on the date of discovery

🏥 Who must file the report when multiple facilities are involved in manufacturing, including contract laboratories and distribution centers

📝 How to complete each section of Form 3486 with line-by-line explanations and real-world examples

⚠️ The consequences of non-compliance, common mistakes that trigger FDA enforcement, and how to avoid them

What Is FDA Form 3486?

FDA Form 3486 serves as the standardized reporting format for Biological Product Deviation Reports. The form enables manufacturers to notify the FDA about manufacturing events—including testing, processing, packing, labeling, storage, holding, or distribution—that may compromise product quality. This reporting system allows the FDA to monitor trends, identify systemic problems, and protect public health.

The form applies to three distinct product categories, each governed by its own regulation. Understanding which regulation applies to your facility determines how you complete the form and where you submit it.

The FDA developed Form 3486 in November 2000 when it published the final rule replacing the term “error and accident” with “biological product deviation.” This change more clearly described reportable events and limited reporting to those events that may affect product safety, purity, or potency.

Who Must File FDA Form 3486?

The responsibility for filing rests with the establishment that had control over the product when the deviation occurred. This distinction matters because biological products often pass through multiple facilities during manufacturing.

Licensed Biological Product Manufacturers

Under 21 CFR 600.14, you must report if you hold the biological product license and had control over the product when the deviation occurred. If you arrange for another person to perform a manufacturing step while the product remains in your control, that step is performed under your control. You must establish procedures for receiving information from that person about all deviations, complaints, and adverse events.

Blood Establishments and Transfusion Services

Under 21 CFR 606.171, the following entities must report:

• Licensed manufacturers of blood and blood components, including Source Plasma
• Unlicensed registered blood establishments
• Transfusion services that had control over the product when the deviation occurred

HCT/P Establishments

Under 21 CFR 1271.350(b), establishments manufacturing non-reproductive HCT/Ps regulated solely under section 361 of the PHS Act must investigate all deviations and report those relating to core CGTP requirements within 45 days.

Real-World Scenario: Contract Laboratory Testing

Consider this scenario: A blood establishment contracts with a test laboratory to perform viral marker testing. The test laboratory incorrectly performs the testing, and the blood establishment distributes the improperly tested product.

The FDA guidance document clarifies that the test laboratory must conduct an investigation but is not required to file a separate report with the FDA. The blood establishment—as the entity that distributed the product—bears the reporting responsibility.

What Events Trigger Mandatory Reporting?

A deviation requires reporting when it meets all three criteria established in the regulations. Understanding these criteria prevents both over-reporting (filing unnecessary reports) and under-reporting (missing mandatory submissions).

The Three-Prong Test for Reportable Deviations

Prong 1: The event either:

• Represents a deviation from current good manufacturing practice, applicable regulations, applicable standards, or established specifications that may affect the safety, purity, or potency of that product; OR
• Represents an unexpected or unforeseeable event that may affect the safety, purity, or potency of that product

Prong 2: The event occurs in your facility or another facility under contract with you

Prong 3: The event involves a distributed product

If the product was never distributed, no report is required—regardless of how serious the deviation was.

Blood Establishment Deviation Examples

The FDA Blood BPD Codes categorize deviations into specific systems. Here are common reportable scenarios:

HCT/P Deviation Examples

For HCT/Ps, only deviations relating to core CGTP requirements trigger reporting. The FDA HCT/P guidance provides extensive examples:

The 45-Day Reporting Timeline

The deadline for submitting Form 3486 is not to exceed 45 calendar days from the date of discovery. However, the regulations state you should report “as soon as possible.”

How to Calculate Your Deadline

The 45-day clock starts on the date you, your agent, or another person performing a manufacturing step acquires information reasonably suggesting a reportable event has occurred. This is called the “date of discovery.”

Critical Distinction: If the event occurred at a contractor’s facility, the date of discovery is when the contractor learns about the deviation—not when they notify you. Your contract should require immediate notification to protect your compliance timeline.

Timeline Comparison: Form 3486 vs. Other Reports

Different regulatory reports have different deadlines. Understanding these distinctions prevents confusion:

The FDA presentation on reporting requirements emphasizes this key point: biologics receive a longer reporting window (45 days versus 3 days for drug products) because of the “potential complexity of biologics and the need for a thorough investigation.”

How to Complete FDA Form 3486: Section-by-Section Guide

Form 3486 consists of four main sections. The FDA’s general instructions provide detailed guidance for each field.

Section A: Facility Information

This section identifies the reporting establishment—the facility that had control over the product when the deviation occurred.

A1-A2: Reporting Establishment Information

Enter your establishment’s name, address, point of contact, telephone number, and email address. You must provide either:

• FDA Establishment Identifier (FEI) number, OR
• CLIA number (for transfusion services exempt from FDA registration)

To obtain your FEI number, use FDA’s FEI Search Portal.

A3-A4: Location Where Deviation Occurred (if different)

Complete this section only if the deviation occurred at a different facility than the reporting establishment. This applies when:

• A Source Plasma collection center reports through corporate headquarters
• A contract manufacturing site experienced the deviation
• An auxiliary facility (donor center, distribution center) had the event

Section B: Biological Product Deviation Information

This section captures the details of what happened, why it happened, and what you plan to do about it.

Understanding BPD Codes

The BPD code system uses a three-level hierarchy:

XX – System affected (e.g., DS = Donor Screening, LA = Labeling, QC = Quality Control)

YY – Subset of system (more specific category)

ZZ – Detailed description (most specific level)

For example, code QC-94-02 means:

• QC = Quality Control & Distribution system
• 94 = Product identified as unsuitable category
• 02 = Due to a donor screening deviation or unexpected event

Section C: Unit/Product Information

This section identifies the specific products affected by the deviation.

C1: Blood Products/Components

For each affected unit, provide:

• Unit number (lot number relating to donor)
• Collection date
• Expiration date
• Product code (from Blood Product Codes list)
• Disposition (transfused, returned, destroyed, etc.)
• Distribution type (In-house or To another facility)
• Notification status (Yes, No, or RN for reverse notification)

C2: Non-Blood Products

For non-blood products including HCT/Ps, vaccines, therapeutics, and diagnostics, provide:

• Lot number
• Expiration date
• Product type (Allergenics, Derivatives, Therapeutics, “351” HCT/Ps, “361” HCT/Ps, etc.)
• Product code (from Non-Blood Product Codes list)
• Disposition
• Notification status

Section D: Additional Comments

Use this section for:

• Additional unit/lot numbers when more than 18 products are affected
• Explanations for missing information
• Clarifications about product disposition or notification

Submission Methods: Electronic vs. Paper

The FDA strongly encourages electronic submission through the eBPDR system for CBER-regulated products.

Electronic Submission

The electronic web-based application provides several advantages:

• Automated validation reduces errors
• Immediate acknowledgment of receipt
• Faster processing time
• Secure transmission

To access the eBPDR system, you need a CBER Online account.

Paper Submission

If you submit by mail, send completed Form 3486 to the appropriate center:

For CBER-regulated products:
Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71-G112
Silver Spring, MD 20993-0002

For CDER-regulated biologics (therapeutic proteins):
Food and Drug Administration, CDER
Office of Pharmaceutical Quality
Office of Quality Surveillance
Attn: CDER DQRS Reports – BPDR Assessment
10903 New Hampshire Avenue
Building 22, RM 4316
Silver Spring, MD 20993-0002

For CDER submissions, email to [email protected] is the preferred method.

Common Mistakes to Avoid

The FDA’s presentation on BPDR requirements identifies the most frequent errors that delay processing and trigger requests for additional information.

Most Common Form 3486 Errors

Investigation Quality Issues

Beyond form completion errors, the FDA identifies substantive investigation deficiencies during inspections and warning letters:

• Failure to open investigations for all errors
• Incomplete documentation of corrective actions
• Failure to close investigations
• Inadequate review by management and quality control unit
• Not identifying root cause or justifying why it cannot be determined

What Happens After You Submit?

After the FDA receives your Form 3486, the agency reviews the report to assess potential public health impact and determine whether additional action is needed.

FDA Review Process

The FDA uses deviation reports to:

• Identify trends across the industry
• Target facilities for inspection
• Initiate recalls when necessary
• Update guidance documents

You may receive a follow-up request for additional information if your initial report was incomplete or unclear.

Potential FDA Actions

Based on the severity and nature of the deviation, FDA may take various actions:

According to FDA FY2024 data, 421 products were recalled during the fiscal year, with contamination issues (microbial, sterility, particulates) accounting for 79% of recalls.

Scenarios When Form 3486 Is NOT Required

Understanding when you are not required to report is equally important to avoid unnecessary submissions that burden both your facility and the FDA.

Products Not Distributed

If you detect a deviation before distribution and either quarantine the product or make appropriate corrections following established procedures, no report is required.

Events Outside Your Control

A blood establishment guidance example illustrates this principle:

Scenario: You distribute Red Blood Cells to a transfusion service. The transfusion service stores the product at the incorrect temperature.

Result: You are not required to report because the event did not occur while the product was under your control. However, if the transfusion service distributed that improperly stored product, they must report.

Events During Transfusion (After Leaving Transfusion Service Control)

Transfusion services are not required to report events occurring during transfusion or administration procedures after the blood product has left their control:

• Patient receives wrong unit due to nursing floor error (if transfusion service labeled and crossmatched correctly)
• Hospital staff does not use filter provided with product
• Product not held at appropriate temperature outside transfusion service prior to transfusion

Non-Core CGTP Deviations for HCT/Ps

For HCT/Ps, only deviations related to the core CGTP requirements listed in 21 CFR 1271.150(b) require reporting. Deviations from other Part 1271 requirements—such as concurrent documentation errors under 21 CFR 1271.270—do not trigger Form 3486 submission.

Reproductive HCT/Ps

Reproductive tissues are specifically exempted from HCT/P deviation reporting requirements under 21 CFR 1271.150(c)(3).

Form 3486 vs. Related FDA Forms and Reports

Facilities handling biological products may encounter multiple reporting requirements. Understanding the distinctions prevents confusion and ensures proper compliance.

Form 3486 vs. Form 483

These forms serve entirely different purposes:

Form 483 is issued by FDA investigators at the conclusion of an inspection when they observe conditions that may constitute violations. You do not file Form 483—you receive it.

Form 3486 vs. Field Alert Report (Form 3331A)

The Field Alert Report applies to small molecule drugs approved under NDAs and ANDAs—not biologics. The shorter 3-day deadline reflects the typically less complex nature of drug product deviations compared to biologics.

Form 3486 vs. Adverse Reaction Reports

For HCT/Ps, establishments must distinguish between:

• Deviation reports (Form 3486) – manufacturing events that may affect safety, purity, or potency
• Adverse reaction reports (MedWatch Form 3500A) – clinical reactions in recipients involving communicable disease transmission

21 CFR 1271.350(a) requires separate 15-day adverse reaction reporting for fatal or life-threatening reactions involving communicable disease. If an adverse reaction results from a deviation, you must submit both reports.

FDA Enforcement: Consequences of Non-Compliance

Failure to report required deviations or submitting incomplete/inaccurate reports exposes your facility to escalating enforcement actions.

Warning Letter Examples

Recent FDA warning letters to biological product manufacturers cite:

• Failure to conduct adequate investigations into critical deviations
• Multiple microbiological contamination events without proper documentation
• Inadequate corrective and preventive actions (CAPA)
• Poor documentation and recordkeeping

A 2024 warning letter to a blood products manufacturer cited multiple failures including:

• 20 of 26 Internal Investigation Reports not completed properly
• Failure to open investigations for errors
• Incomplete documentation of corrective actions
• Failure to close investigations

Enforcement Statistics

According to FDA enforcement data for FY2025:

• Warning letters to biologics manufacturers increased from 15 (FY2024) to 26 (FY2025)
• The FDA conducted 694 more inspections compared to the previous year
• Between July and December 2025, the FDA issued 327 warning letters—a 73% increase over the same period in 2024

Potential Penalties

Non-compliance with deviation reporting can result in:

Do’s and Don’ts for Form 3486 Compliance

Do’s

✅ Report as soon as possible – The 45-day limit is a maximum, not a target. Early reporting demonstrates commitment to quality.

✅ Establish procedures for receiving contractor information – Your contracts should require immediate notification of deviations affecting products under your control.

✅ Document everything – Complete investigations within 30 days when possible; document justification for any extensions.

✅ Use the standardized form – Custom reports attached to Form 3486 are discouraged and delay processing.

✅ Verify your facility registration – Ensure your FEI number matches current FDA records before submitting.

Don’ts

❌ Don’t include patient, donor, or employee names – Personal identification information is prohibited on Form 3486.

❌ Don’t use Form 3486 for fatality reports – Blood transfusion fatalities require separate 7-day reporting under 21 CFR 606.170(b).

❌ Don’t combine multiple BLA products on one form – Each product requires a separate report.

❌ Don’t submit blank pages – Only include completed pages (pages 2, 3, 4, and 7 should be omitted if additional space is not needed).

❌ Don’t wait until CAPA is complete – You do not have to implement corrective actions before filing the report.

Pros and Cons of the 45-Day Reporting System

Pros

✅ Adequate investigation time – The 45-day window allows thorough root cause analysis, especially for complex biologics where deviation sources may not be immediately apparent.

✅ Quality over speed – Unlike the 3-day FAR requirement for drugs, the longer timeline produces more accurate and complete reports.

✅ Standardized format – Form 3486 creates consistent data that enables FDA trend analysis across the industry.

✅ Electronic submission option – The eBPDR system reduces errors and speeds processing.

✅ Clear regulatory framework – The three-prong test (deviation + your facility/contractor + distributed product) provides clear guidance on what requires reporting.

Cons

❌ Public health delay – Serious deviations may not reach FDA for up to 45 days after discovery, potentially delaying public health responses.

❌ Complexity for multi-facility operations – Determining which facility must report when deviations occur across contract networks requires careful analysis.

❌ Resource intensive – Complete investigations, root cause analysis, and CAPA development within 45 days strains quality resources.

❌ Core CGTP limitation for HCT/Ps – Deviations from non-core requirements go unreported, potentially leaving gaps in FDA’s safety surveillance.

❌ Enforcement inconsistency – Warning letter issuance varies, creating uncertainty about compliance thresholds.

Key Entities and Organizations

Understanding the roles of various entities helps navigate the deviation reporting system.

FDA Centers

Center for Biologics Evaluation and Research (CBER) – Regulates blood, vaccines, allergenics, tissues, cellular and gene therapies, and most biological products. Receives the majority of Form 3486 submissions.

Center for Drug Evaluation and Research (CDER) – Regulates therapeutic proteins and biosimilars. Receives BPDRs for CDER-regulated biologics at [email protected].

Establishment Types

Licensed Blood Establishment – Holds FDA license to manufacture blood and blood components for interstate commerce.

Unlicensed Registered Blood Establishment – Registered with FDA but does not hold a license; typically processes blood within state lines.

Transfusion Service – Performs compatibility testing and transfuses blood; may or may not be registered with FDA depending on activities.

361 HCT/P Establishment – Manufactures HCT/Ps meeting all criteria under 21 CFR 1271.10(a); regulated solely under section 361 of PHS Act.

351 HCT/P Establishment – Manufactures HCT/Ps regulated as biological products; subject to biologics license application (BLA) requirements.

FAQs About FDA Form 3486

Is FDA Form 3486 required for products that were never distributed?

No. The regulations require that the deviation must involve a distributed product. If you detect and quarantine or correct the deviation before distribution, no report is required.

Can a contract laboratory file Form 3486 on my behalf?

No. The license holder or establishment that had control over the distributed product must file. Contract laboratories must investigate and notify you, but you submit the report.

Do I need to complete my CAPA before filing Form 3486?

No. The regulations state you do not have to implement corrective actions at the time of filing. Include your intended follow-up plans in Section B7.

Is Form 3486 required for autologous HCT/P donors?

No. Donor eligibility determination, screening, and testing requirements do not apply to autologous donors under 21 CFR 1271.90(a)(1).

What happens if I miss the 45-day deadline?

Report anyway. Late reports may trigger FDA scrutiny and potential warning letter observations, but failing to report at all creates greater regulatory risk.

Can I submit one Form 3486 for multiple affected products?

Yes, if it’s a single event. If one deviation affects multiple units/lots, submit one report listing all affected products. If deviations are separate events, submit separate reports.

Do transfusion services need to report events occurring on nursing floors?

No. Events during transfusion administration after the product left transfusion service control do not require reporting by the transfusion service.

Is adverse reaction reporting the same as deviation reporting?

No. Adverse reactions involving communicable disease require separate reporting under 21 CFR 1271.350(a) using MedWatch Form 3500A. Both reports may be needed if a deviation causes an adverse reaction.

What if I cannot determine the root cause?

State it explicitly. Indicate in Section B6 that after investigation, a root cause cannot be determined. The FDA expects honest assessments, not fabricated conclusions.

Are reproductive HCT/Ps subject to deviation reporting?

No. Reproductive tissues are specifically exempted from HCT/P deviation reporting requirements under 21 CFR 1271.150(c)(3).